CEO Robert L. Cucin, M.D. of BioSculpture Technology, Inc. to Be Interviewed on Clear Channel - iHeart Business Talk Radio''s "The Trader''s Network"
Live Interview to Air April 11th 2015 Hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT
(firmenpresse) - WEST PALM BEACH, FL -- (Marketwired) -- 04/10/15 -- BioSculpture Technology, Inc., a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or "belly" fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus, announced today that Chief Executive Officer (CEO) Robert L. Cucin, M.D. will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio''s "The Trader''s Network" Show. In this exclusive interview, Dr. Cucin will discuss how the company believes their method and device will save lives, improve life outcomes, and significantly reduce healthcare costs. U.S. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel''s nationally syndicated iHeart Radio stream.
April 11, 2015
1:30pm ET | 10:30am PT | 12:30pm CT (U.S.)
Clear Channel - iHeart
The Trader''s Network
Michael Yorba
BioSculpture Technology, Inc. ("BST") is a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or "belly" fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our method and device will save lives, improve life outcomes, and significantly reduce healthcare costs.
BST''s Corporate Mission is to be the world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: the bariatric market; and the liposuction and body sculpting market; fat autograft and adipocyte-derived stem cell processing markets.
is a practicing plastic surgeon in Manhattan affiliated with The Presbyterian - New York Hospital, and New York University Downtown Hospitals. He received his undergraduate training from Cornell University where he received his B.A. and graduated magna cum laude in chemistry and with distinction in all subjects. He was granted his M.D. from Cornell Medical School and did both his General Surgery and Plastic & Reconstructive Surgery residences at The New York Hospital - Cornell University Medical Center. He is board-certified in plastic surgery and legal medicine and has a teaching appointment at the Weill Cornell Medical School.
He received a Juris Doctorate from Fordham Law School and is duly admitted to the New York, New Jersey and D.C. Bars and the American Trial Lawyers Association. His original research has been the subject of numerous contributions to the medical literature and he has published books in the fields of both medicine and law. Dr. Cucin funded the to support his academic research and employs his combined degrees and experience in heading a Biotechnology Analysis and Advisory Service to assist new and established companies in developing and either manufacturing or licensing their biomedical intellectual property and to perform due diligence for investors interested in providing the start-up funds for ventures based upon new technology. Concentrating in finance, Dr. Cucin obtained an M.B.A. from Columbia Business School and is a member of Mensa.
Twenty years ago Dr. Cucin set up as a Research and Development company to perfect biomedical dermatologicals and devices. That company now has an extensive international patent portfolio and it is from that portfolio that first , then the , and now the separate company was funded to concentrate on the further refinement, manufacture and worldwide distribution of the most advanced body contouring, tissue aspiration, collecting, and processing technology of that portfolio. It is the application of that technology to the treatment of obesity and Company''s emphasis on its accelerated development which warrants this interview.
Clear Channel''s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. .
For the past six years "The Traders Network Show" has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am - 7:30am and 2pm - 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It''s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow''s ideas today" on iHeart Radio and Clear Channel''s The Traders Network Show. To inquire about being a guest on this show please contact "1800pr" at .
Image Available:
Image Available:
1701 South Flagler Drive
West Palm Beach, Florida 33401
212.977.5400
Matthew BIRD
President
1-800-PublicRelations, Inc.
917.409.8211
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2015 - 05:15 Uhr
Sprache: Deutsch
News-ID 1350440
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WEST PALM BEACH, FL
Phone:
Kategorie:
Women's Interest
Anmerkungen:
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CEO Robert L. Cucin, M.D. of BioSculpture Technology, Inc. to Be Interviewed on Clear Channel - iHeart Business Talk Radio''s "The Trader''s Network"
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSculpture Technology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
